These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27777939)

  • 21. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2018 Jun; 93(6):824-840. PubMed ID: 29878489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
    Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2020 Jan; 95(1):97-115. PubMed ID: 31736132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
    Meggendorfer M; Roller A; Haferlach T; Eder C; Dicker F; Grossmann V; Kohlmann A; Alpermann T; Yoshida K; Ogawa S; Koeffler HP; Kern W; Haferlach C; Schnittger S
    Blood; 2012 Oct; 120(15):3080-8. PubMed ID: 22919025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center.
    Wang C; Wang Z; Meng F; Luo L; Liu X; Shi J; Huang L
    Int J Gen Med; 2022; 15():7843-7854. PubMed ID: 36644378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moving towards a uniform risk stratification system in CMML - How far are we?
    Chan O; Padron E
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101131. PubMed ID: 32460982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.
    Hunter A; Padron E
    Curr Hematol Malig Rep; 2021 Jun; 16(3):247-255. PubMed ID: 33660195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic myelomonocytic leukemia - a review.
    Thomopoulos TP; Bouhla A; Papageorgiou SG; Pappa V
    Expert Rev Hematol; 2021 Jan; 14(1):59-77. PubMed ID: 33275852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 32. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
    Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
    Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
    Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment.
    Elmariah H; DeZern AE
    Curr Hematol Malig Rep; 2019 Jun; 14(3):154-163. PubMed ID: 31093889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
    Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
    Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jun; 91(6):631-42. PubMed ID: 27185207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization.
    Sallman DA; Padron E
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S50-5. PubMed ID: 26297278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico.
    Jiang Z; Sun X; Wu Z; Alhatem A; Zheng R; Liu D; Wang Y; Kumar D; Xia C; You B; Wang H; Liu C; Jiang JG
    Oncotarget; 2020 Nov; 11(47):4411-4420. PubMed ID: 33315966
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Kwon A; Ibrahim I; Le T; Jaso JM; Weinberg O; Fuda F; Chen W
    Leuk Res Rep; 2022; 17():100323. PubMed ID: 35586707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.
    Ball M; List AF; Padron E
    Blood; 2016 Nov; 128(20):2381-2387. PubMed ID: 27707735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.